Louis Moore Bacon's TSHA Position Overview
Louis Moore Bacon (via Moore Capital Management, Lp) currently holds 328,831 shares of Taysha Gene Therapies, Inc. (TSHA) worth $1.47 M, representing 0.03% of the portfolio. First purchased in 2026-Q1, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Louis Moore Bacon has initiated a new position in TSHA, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Louis Moore Bacon's Taysha Gene Therapies (TSHA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Taysha Gene Therapies (TSHA) Trades by Louis Moore Bacon
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +328,831 | New Buy | 328,831 | $4.47 |
Louis Moore Bacon's Taysha Gene Therapies Investment FAQs
Louis Moore Bacon first purchased Taysha Gene Therapies, Inc. (TSHA) in Q1 2026, acquiring 328,831 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Louis Moore Bacon has held Taysha Gene Therapies, Inc. (TSHA) for 1 quarters since Q1 2026.
Louis Moore Bacon's largest addition to Taysha Gene Therapies, Inc. (TSHA) was in Q1 2026, adding 328,831 shares worth $1.47 M.
According to the latest 13F filing for Q1 2026, Louis Moore Bacon's firm, Moore Capital Management, Lp, owns 328,831 shares of Taysha Gene Therapies, Inc. (TSHA), valued at approximately $1.47 M.
As of the Q1 2026 filing, Taysha Gene Therapies, Inc. (TSHA) represents approximately 0.03% of Louis Moore Bacon's publicly disclosed stock portfolio, making it one of their key holdings.
Louis Moore Bacon's peak holding in Taysha Gene Therapies, Inc. (TSHA) was 328,831 shares, as reported at the end of Q1 2026.